| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Leonard Sank last filed a Form 4 in June 2025, as Director at ORMP. Leonard Sank's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 134,531 shares of ORMP. Net of sales, the ORMP filings show accumulation of 80,837 shares.
Leonard Sank has 16 Form 4 filings on record from February 2015 to June 2025, all as Director at Oramed Pharmaceuticals (ORMP), 2015–2025.
The 26 reported transactions were 9 stock awards, 7 open-market purchases, 4 option exercises and 3 option or other derivative awards, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 3 purchases worth about $273K and no sales.
The largest open-market purchase was 54,517 shares of ORMP at an average $3.59 on July 18, 2019, about $196K.
Shares as reported in the last Form 4 for each company; the most recent is from June 2025. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.